Centers for Disease Control and Prevention, Atlanta, GA, United States.
Vaccine. 2012 Apr 27;30 Suppl 1:A30-5. doi: 10.1016/j.vaccine.2011.11.093.
In recent years, two live, oral rotavirus vaccines have been successfully tested in developing and industrialized countries, and both vaccines are now recommended by the World Health Organization for all children worldwide. Both immunogenicity and efficacy of these rotavirus vaccines has been lower in developing compared to industrialized settings. We reviewed the data on the effect of trivalent OPV on the immunogenicity and efficacy of two rotavirus vaccines currently recommended by the WHO. While rotavirus vaccines have not affected immune responses to OPV, in general, the immune responses (i.e., antibody levels) to rotavirus vaccination were lower when rotavirus vaccines were co-administered with OPV. Limited data suggests that the interference is greater after the first dose of OPV, presumably because the first dose is associated with greatest intestinal replication of vaccine polio virus strains, and this interference is largely overcome with subsequent rotavirus vaccine doses. Despite the lower immunogenicity, one large efficacy study in middle income Latin American countries showed no decrease in protective efficacy of rotavirus vaccine in infants receiving concurrent OPV. While these data are encouraging and support simultaneous administration of rotavirus vaccines and OPV, additional evidence should be gathered as rotavirus vaccines are used more widely in developing country settings, where OPV is routinely used, rather than inactivated polio vaccine.
近年来,两种活的、口服轮状病毒疫苗已在发展中国家和工业化国家成功进行了测试,这两种疫苗现在都被世界卫生组织推荐给全世界所有儿童使用。与工业化国家相比,这些轮状病毒疫苗在发展中国家的免疫原性和功效都较低。我们回顾了关于三价 OPV 对世界卫生组织目前推荐的两种轮状病毒疫苗的免疫原性和功效的影响的数据。虽然轮状病毒疫苗一般不会影响 OPV 的免疫反应,但轮状病毒疫苗与 OPV 同时使用时,轮状病毒疫苗的免疫反应(即抗体水平)较低。有限的数据表明,在接种第一剂 OPV 后干扰更大,大概是因为第一剂与疫苗脊髓灰质炎病毒株在肠道中的最大复制有关,并且这种干扰在随后的轮状病毒疫苗剂量中基本得到克服。尽管免疫原性较低,但在中低收入的拉丁美洲国家进行的一项大型疗效研究表明,接受同时接种 OPV 的婴儿的轮状病毒疫苗的保护效力没有降低。虽然这些数据令人鼓舞,并支持轮状病毒疫苗和 OPV 的同时接种,但应在轮状病毒疫苗在常规使用 OPV 的发展中国家更广泛使用的情况下收集更多证据,而不是使用灭活脊髓灰质炎疫苗。